TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Shrinker Use on Healing and Volume

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Recently undergone primary transtibial amputation~* Patients between ages of 18 and 100 years of age~Exclusion Criteria:~* Undergone previous amputations above the Symes level

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shrinker (Type: ACTIVE_COMPARATOR): Patients receive 20-30 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
- No Shrinker (Type: NO_INTERVENTION): Control group - participants will not receive an intervention (compression shrinker).
- Shrinker 2 (Type: ACTIVE_COMPARATOR): Patients receive 30-40 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-75 yr~* Willingness to provide written informed consent~* Ability to understand the study procedures~Exclusion Criteria:~* Life expectancy \< 3 months~* Claustrophobia~* Allergy to iodinated contrast~* Treatment incompliance~* Pregnancy~* Highly HLA-sensitized patients~* Severe dyslipidemia or proteinuria~* Severe leucopenia or thrombocytopenia~* GFR \< 30 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- everolimus-based immunosuppression (Type: EXPERIMENTAL): immunosuppression with everolimus, prednisone and mycophenolate
- standard immunosuppression (Type: ACTIVE_COMPARATOR): immunosuppression with tacrolimus, prednisone and mycophenolate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening).~* Ability to follow study instructions, complete study assessment tools with minimal assistance and no alteration to the assessment tools, and likely to complete all required visits.~* Participant meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia as determined by Structured Clinical Interview for DSM-5 (SCID-5).~* Positive and Negative Syndrome Scale (PANSS) total score \>= 70 and \<= 120 at Visit 1 and Visit 2 (Day 1).~* Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms; P1: delusions; P2: conceptual disorganization; P3: hallucinatory behaviour; P6: suspiciousness/persecution at Visit 1 and Visit 2.~Exclusion Criteria:~* Currently meeting DSM-5 criteria for any of the following:~* Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders~* Bipolar I and II disorder~* Autism spectrum disorder, intellectual development disorder, delirium, major/minor neurocognitive disorder~* History of meeting DSM-5 criteria for substance-related disorders (excluding caffeine-related and tobacco-related disorders) within the prior 3 months before Visit 1.~* Prior participation in any clinical trials involving experimental or investigational drugs within 6 months before Visit 1 or planned during the study.~* Female Participants who are pregnant, planning to become pregnant during the course of the study, or are currently lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine 4.5 mg/day (Open-label Treatment Period) (Type: EXPERIMENTAL): Cariprazine 1.5 mg capsules orally once daily at Week 1, titrated to 3.0 mg capsules orally once daily at Week 2 and then titrated to 4.5 mg orally once daily from Week 3 through Week 18 in the Open-label Treatment Period.
- Placebo (Double-blind Treatment Period) (Type: PLACEBO_COMPARATOR): Cariprazine placebo-matching capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
- Cariprazine 3.0 mg/day (Double-blind Treatment Period) (Type: EXPERIMENTAL): Cariprazine 3.0 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
- Cariprazine 4.5 mg/day (Double-blind Treatment Period) (Type: EXPERIMENTAL): Cariprazine 4.5 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Golimumab for the Treatment of Refractory Behcet's Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All participants fulfill the proposed International Criteria for BD, either ISG (International Study Group) criteria(1990) or ICBD(International Conference on Behcet's Disease) criteria(2013).~* All participants present with refractory BDU, acute onset uveitis, either posterior segment involvement or panuveitis, with difficulty tapering corticosteroids while being treated with at least one of the commonly used immunosuppressants, without severe extraocular manifestations.~Exclusion Criteria:~* Patients with impaired hepatic and renal function, other severe ocular diseases, active tuberculosis, viral hepatitis, malignancy, pregnancy, congestive heart failure, or had biologics treatment within three months will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Golimumab for refractory BDU (Type: EXPERIMENTAL): This study is a self-control study and all the participants will be enrolled in the interventional arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject participated in the preceding placebo-controlled Phase 3 study ANB019-301 and completed at least the Week 1 visit of the ANB019-301 study without the use of rescue/prohibited medication for GPP~* Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment~Exclusion Criteria:~* Use of prohibited medications between the last visit of the ANB019-301 study and the Day 1 visit of the ANB019-302 study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV +SC Imsidolimab (Type: ACTIVE_COMPARATOR): IV loading dose followed by subcutaneous Imsidolimab
- SC Imsidolimab (Type: ACTIVE_COMPARATOR): Subcutaneous Imsidolimab
- SC Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous Placebo
- Standard of Care (Type: NO_INTERVENTION): Any available therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Infants Fed an Amino Acid-based Formula

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is judged to be in good health as determined from subject's medical history~* Subject is from a full-term birth with a gestational age of 37-42 weeks~* Subject's birth weight was ≥ 2490 g (\~5 lbs. 8 oz.)~* Subject has been documented to have CMPA and/or multiple food allergies, FPIES or gastrointestinal eosinophilic disorders.~* Subject is experiencing persistent feeding intolerance symptoms including any of the following: regurgitation/vomiting associated with feeding (within 1 hour), constipation, diarrhoea, hematochezia (blood in the stool), crying, gassiness (wind), and/or skin rash/eczema.~* Parent(s) confirm their intention to feed their infant study product during the study period.~* Parent(s) confirm their intention not to administer vitamin or mineral supplements to their infant from enrolment through the duration of the study, unless instructed otherwise by their healthcare professional.~* Infant using medications (OTC medications for gas \[wind\]), home remedies (such as juice for constipation), herbal preparations, prebiotics, probiotics or rehydration fluids that might affect Gl tolerance may not be enrolled unless the parent agrees to discontinue the use of these agents prior to enrolment or a healthcare professional recommends their continued use.~* Subject's parent(s) has voluntarily signed and dated an ICF, approved by an IEC/IRB and provided applicable privacy regulation authorisation prior to any participation in the study.~Exclusion Criteria:~* Subject is receiving steroids or antibiotics~* Subject is tube-fed~* Subject has received an amino acid-based formula~* Subject has been diagnosed with: Short bowel syndrome, Inflammatory bowel disease, Pancreatic disease, Protein maldigestion (malnutrition), Mast cell disorder~* Subject is participating in another study that has not been approved as a concomitant study by AN

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Amino Acid-Based Experimental Study Formula (Type: EXPERIMENTAL): Single-Arm Study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring of Safety and Tolerance of PICOPREP in Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for treatment with PICOPREP® for bowel cleansing prior to endoscopic examination or surgery~Exclusion Criteria:~* Patients in which prescription of PICOPREP® is contraindicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PICOPREP treatment (Type: None): PICOPREP powder for oral solution according to standard clinical practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device When Collected Through Peripheral Intravenous Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>19 years old~Exclusion Criteria:~* Not a good candidates for direct-to-media (DTM) technique

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Initial Specimen Diversion Device (ISDD) (Type: EXPERIMENTAL): The ISDD will be used to collect the blood culture.
- Lab standard practice (LSP) (Type: ACTIVE_COMPARATOR): The ISDD will not be used to collect the blood culture. Standard blood culture specimen collection kits will be utilized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* In the 72 hours prior to study entry, participant has been diagnosed with isolated HIT, as defined by an unexplained platelet count drop of over 50% that occurs after exposure to UFH (UnFractionated Heparin)/LMWH (Low Molecular Weight Heparin) at any time in the 4 to 14 days before the positive heparin-PF4 antibody test was sent(even if the person is no longer on UFH/LMWH)~* Currently hospitalized~* Available for study follow-up for at least 28 days after study entry~* No contraindications to ultrasound examination of upper and lower extremities~* For participants less than 7 years old, no contraindications to ultrasound examination of abdomen~* Participants are eligible whether or not they are receiving any therapy for isolated HIT~Exclusion Criteria:~* Documented new venous or arterial thrombosis while on heparin~* Pregnant~* Ongoing active bleeding (as determined by the site investigator)~* Currently using a extracorporeal membrane oxygenator, chronic veno-venous hemofiltration, left ventricular support device, intra-aortic balloon pump, or any other mechanical heart pump~* Coronary artery bypass surgery occured within 96 hours prior to the time when the positive HIT test was drawn

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isolated HIT (Type: None): Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Post-Operative cancer patients experiencing atrial fibrillation and otherwise clinically ready to be discharged.~* Must attend two outpatient visits at MSKCC's cardiology practice during the study period, as specified by the participant's Attending.~* Must be older than 21 years of age.~Exclusion Criteria:~* Non-English speaking patients

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- post op cancer patients experiencing atrial fibrillation (Type: None): This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Botox for Non-surgical Lateral Release in Patellofemoral Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* retropatellar knee pain~* pain with two of: prolonged sitting, climbing stairs, squatting, running, kneeling, hopping, jumping~* pain with patellar palpation~* symptoms minimum 1 month~* Visual Analog Scale for pain (VAS) usual pain 4 of 10 on VAS \[0-10 scale, anchors 0 = no pain, 10 = worst pain imaginable\]~Exclusion Criteria:~* history knee surgery~* history patellar dislocation~* clinical evidence of meniscal lesion, ligamentous instability, traction apophysitis around the patellofemoral complex, patellar tendon pathology, chondral damage, osteoarthrosis, spinal referred pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
- 2 (Type: PLACEBO_COMPARATOR): Placebo injection + exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Massage Therapy in Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of JIA (ILAR classification)~* Age 5 to 17 years~* Ability to speak/read French or English; one caregiver per child will be recruited;~* Presence of pain, defined as: pain reported by the child and/or caregiver, and/or joint tenderness and/or stress pain in at least 1 joint during physical examination performed by rheumatologist. Pain reported by the child/caregiver is not a prerequisite because some children develop behaviors and guarding postures to avoid pain~* Absence of anticipated change in treatment. If, during the study, a change in treatment is necessary, the change will be recorded but the child will not be withdrawn~* Stable dosages of medications and absence of intra-articular corticosteroid injections for 4 weeks prior to enrolment~* Eligibility confirmed by child's rheumatologist.~Exclusion Criteria:~* No current MT~* Systemic arthritis with quotidian fevers~* Acute infection~* Open skin lesion~* Fibromyalgia~* Sleep apnea~* Medications: anticoagulants, muscle relaxants, analgesic medications (acetaminophen allowed)~* Pregnancy.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Massage therapy & standard care (Type: EXPERIMENTAL): Massage therapy will be provided by caregiver for 15 minutes at bedtime at home, every night, for a 2-week period.~Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.
- Standard care (Type: ACTIVE_COMPARATOR): Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Early Versus Late Switch to Lapatinib-Capecitabine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* Women with ErbB2+ MBC (ErbB2 expression confirmed by immunohistochemistry or FISH/CISH, either in the primary tumor or in the metastasis, according to the institution's common practice);~* Older than 18 years old;~* Have received prior treatment with trastuzumab-containing regimen for ErbB2+ breast cancer;~* Progressing after trastuzumab-containing regimen either used for the treatment of metastatic disease or progressing after adjuvant /neoadjuvant trastuzumab treatment;~* Eligible to start standard treatment with Lapatinib-capecitabine at conventional doses, in the community setting;~* Signed consent to participate and release information for this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients on second line treatment (Type: None): Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
- Patients on third or more lines treatment (Type: None): Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval